GNCA GENOCEA BIOSCIENCES

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Genocea Bioscience, Inc. (NASDAQ: GNCA) (“Genocea” or the “Company”) securities during the period between May 5, 2017 and September 25, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 2, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Genocea securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Genocea's finances were insufficient to support Phase 3 trials of GEN-003.

According to the complaint, following the September 25, 2017 announcement that the Company was halting spending and activities on GEN-003, exploring strategic alternatives for the drug, and cutting 40% of its workforce, the value of Genocea shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Genocea securities purchased on or after May 5, 2017 and September 25, 2017 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/casesandinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

EN
17/11/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GENOCEA BIOSCIENCES

 PRESS RELEASE

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

Genocea Announces Wind Down of Operations and Delisting From NASDAQ CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the ...

 PRESS RELEASE

Genocea Initiates Restructuring and Announces Plan to Explore Strategi...

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company,...

 PRESS RELEASE

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences to Host Investor Webinar CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripher...

 PRESS RELEASE

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conferenc...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of t...

 PRESS RELEASE

Genocea Provides Fourth Quarter 2021 Corporate Update

Genocea Provides Fourth Quarter 2021 Corporate Update Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy ca...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch